acetylsalicylic acid/dipyridamole

{{short description|Pharmaceutical combination}}

{{Drugbox

| image = Aspirin and dipyridamole.svg

| type = combo

| component1 = Acetylsalicylic acid

| class1 = Anticoagulant

| component2 = Dipyridamole

| class2 = Anticoagulant

| tradename = Aggrenox, Asasantin

| Drugs.com = {{Drugs.com|UK|asasantin-retard-capsules-leaflet}}

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration = Oral

| ChemSpiderID = 121018

| CAS_number_Ref = {{cascite|correct|CAS}}

| CAS_number = 50-78-2

| CAS_number2_Ref = {{cascite|correct|CAS}}

| CAS_number2 = 58-32-2

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = R16CO5Y76E

| UNII2_Ref = {{fdacite|correct|FDA}}

| UNII2 = 64ALC7F90C

| ATCvet =

| ATC_prefix = B01

| ATC_suffix = AC30

| PubChem = 137329

| DrugBank =

| KEGG = D11615

}}

The combination drug acetylsalicylic acid/dipyridamole (trade names Aggrenox, Asasantin) is a drug combination of:[http://www.fass.se/LIF/produktfakta/artikel_produkt.jsp?NplID=19971212000035&DocTypeID=7&UserTypeID=2 FASS (the Swedish official drug catalog) > Asasantin] Last update: 2009–08–17

• Acetylsalicylic acid (Aspirin) - An extremely common NSAID that has anticoagulant effects
• Dipyridamole, a drug that inhibits platelet activation{{DorlandsDict|three/000030395|Dipyridamole}} when given chronically and causes vasodilation when given at high doses over short time.

The combination acts as an extended release formulation and is primarily used for platelet inhibition in patients suffering, or at risk from, acute coronary events and stroke.{{cite journal| vauthors = Malinin AI, Eisert RM, Atar D, Barkagan Z, Serebruany VL |s2cid=71396361|title=Aggrenox (Extended-Release Dipyridamole and Low-Dose Aspirin in Combination): Protecting Platelets from Excessive Activation in Patients with Vascular Events|journal=Heart Drug|date=2002|volume=2|issue=2|pages=93–104|doi=10.1159/000063427}} Its use has been shown to be better than the use of either dipyridamole or aspirin alone.{{cite journal | vauthors = Serebruany VL, Malinin AI, Sane DC, Jilma B, Takserman A, Atar D, Hennekens CH | title = Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial | journal = European Journal of Pharmacology | volume = 499 | issue = 3 | pages = 315–24 | date = September 2004 | pmid = 15381054 | doi = 10.1016/j.ejphar.2004.07.114 }}